Nanobiotix Stock Rises 2.63% at Close with New Target
The stock of Nanobiotix closed up 2.63% this Monday, February 2, 2026, at 17.92 euros. This increase follows a recent price target upgrade by Jefferies at the end of January. Over one year, the French biotechnology company has seen a spectacular increase of 412%.
Strong Analyst Support for Nano-Oncology Specialist
The nano-oncology specialist benefits from marked support from analysts. Jefferies recently adjusted its price target to 21.50 euros, up from 21 euros previously, while maintaining its buy recommendation dated January 29. This new threshold suggests a potential appreciation of 20% from the current price. On the other hand, Oddo BHF shows even more pronounced optimism with a target set at 28 euros since mid-December, maintaining its outperformance advice. This valuation implies a margin for progression for the stock, reflecting the high expectations placed on the company by the French broker. Both institutions share a favorable outlook on the company's prospects.
Technical Analysis Shows Strong Upward Trend
From a chart perspective, the stock price is significantly above its 200-day moving average of 11.15 euros, confirming the underlying bullish trend that has been established over twelve months. The relative strength index stands at 52, indicating a balance between buyers and sellers in a neutral zone. The stock faces immediate resistance at 19.88 euros, a level it must surpass to continue its ascent. Conversely, a support level is forming around 17.24 euros, close to the current price. The one-month volatility is at 14.02%, reflecting significant fluctuations characteristic of the biotechnology sector. With a beta of 0.32, the stock shows limited sensitivity to overall market movements, operating relatively independently of benchmark indices.
